The e fund csi technology 50 etf in Southeast Asia led the gains, while this week funds went against the trend to buy the Huaxia CSI 100 ETF.
The latest interpretation of the "Global Perspective · Betting on China" Top Ten Core etf for 2024 (Weekly Report)
The army of low-cost broad-based ETFs is expanding, star 100 ETF officially announced a fee reduction, with many similar products already reaching low fee levels.
①Fee reduction has become a common tool for fund companies to seize market share in the etf market. ②In October alone, many top institutions such as Huaxia, Bosh, Silver China, Penghua, and Fuguo have successively joined the army of lowering fees for broad-based ETFs.
"Hard technology" is popular across the board, with the e fund artificial intelligence ETF up 8% in October, and the technology innovation 100 ETF Huaxia rising 30% in the past two months.
Latest interpretation (monthly report) of the top 10 core ETFs in the "Global Vision · Betting on China" in 2024
Bank of America added to its position in technology giants such as Microsoft (MSFT.US) and Apple (AAPL.US) in Q2. Put options on the Nasdaq 100 ETF have become the new favorite.
Bank of America submitted its second quarter holding report (Form 13f) until June 30, 2024.
Wells Fargo & Co re-purchased the "Seven Giants" in Q2 and bought put options on the Nasdaq 100 ETF.
According to the Securities and Exchange Commission (SEC) disclosure, Wells Fargo & Co filed its second quarter (Q2) form 13f holding report ending on June 30, 2024.
Policy supports the innovative development of the entire biomedical industry chain, and the Sci-Tech Innovation 100 ETF Fund (588220) has risen strongly by 3.48%.
The Sci-Tech Innovation 100 Index leads the broad-based market. As of 10:40, the constituent stock Di Zhe Pharmaceutical of the SCI-TECH Innovation 100 ETF Fund rose more than 8%, Remegen and Eyebright Medical Technology (Beijing) Co., Ltd. also rose more than 5%, and the SCI-TECH Innovation 100 ETF Fund (588220) rose 3.48%, with a turnover of more than 0.24 billion, ranking first among similar products. At the same time, since the beginning of the year, the daily turnover of the SCI-TECH Innovation 100 ETF Fund has reached 0.66 billion, also ranked first among similar products. On the news front, the head of the National Medical Products Administration presided over a meeting on July 30th to study and deploy the reform of clinical trial evaluation and approval for innovative drugs, and approved the pilot of optimizing the clinical trial evaluation and approval of innovative drugs.